✦ LIBER ✦

PROSPECTIVE DETECTION OF CLINICALLY RELEVANT PROSTATE CANCER IN THE PROSTATE SPECIFIC ANTIGEN RANGE 1 TO 3 NG./ML. COMBINED WITH FREE-TO-TOTAL RATIO 20% OR LESS: THE AARAU EXPERIENCE

✍ Scribed by RECKER, FRANZ; KWIATKOWSKI, MACIEJ K.; HUBER, ANDREAS; STAMM, BERNHARD; LEHMANN, KURT; TSCHOLL, RETO

Book ID: 122068289
Publisher: Lippincott Williams and Wilkins
Year: 2001
Tongue: English
Weight: 50 KB
Volume: 166
Category: Article
ISSN: 0022-5347
DOI: 10.1016/S0022-5347(05)65850-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Percent Free Prostate Specific Antigen i

Percent Free Prostate Specific Antigen in the Total Prostate Specific Antigen 2 to 4 ng./ml. Range Does Not Substantially Increase the Number of Biopsies Needed to Detect Clinically Significant Prostate Cancer Compared to the 4 to 10 ng./ml. Range

✍ Haese, Alexander; Dworschack, Robert T.; Partin, Alan W. 📂 Article 📅 2002 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 74 KB

A Multicenter Study of [-2]Pro-Prostate

A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range

✍ Catalona, William J.; Partin, Alan W.; Sanda, Martin G.; Wei, John T.; Klee, Geo 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 195 KB

MP69-04 FUTURE RISK FOR INTERMEDIATE OR

MP69-04 FUTURE RISK FOR INTERMEDIATE OR HIGH RISK PROSTATE CANCER IN MEN WITH BASELINE PSA OF 1-3NG/ML AND LOW FREE-TO-TOTAL PSA-RATIO IN A PROSPECTIVE POPULATION-BASED SCREENING TRIAL (ERSPC AARAU)

✍ Randazzo, Marco; Beatrice, Josef; Huber, Andreas; Grobholz, Rainer; Manka, Lukas 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 398 KB